We use cookies for a better user experience. Read our Privacy Policy

I Agree

Human Papillomavirus Vaccine Market

Human Papillomavirus Vaccine Market (Valence - Bivalent, Quadrivalent, Nonavalent; Indication - Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Oropharyngeal Cancer, Genital Warts; Distribution Channel - Physicians, Wholesalers, Physician Distributors, Government Entities, Public and Private Alliances) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Human Papillomavirus Vaccine Market: Snapshot

Human papillomaviruses cause various types of cancers such as cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, oropharyngeal cancer, and genital warts. The human papillomavirus infection can be prevented by the vaccination against human papillomavirus. The human papillomavirus vaccine market was valued approximately US$ 2.0 Bn in 2016 and is anticipated to reach US$ 3.5 Bn by 2025, expanding at a CAGR of over 5.0% from 2017 to 2025. Approval of new human papillomavirus vaccines in various countries is likely to fuel the human papillomavirus vaccine market from 2017 to 2025.

Human papillomaviruses is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of human papillomavirus have been characterized. Increasing prevalence of various cancers caused by human papillomavirus is expected to drive the market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), human papillomavirus is the most common sexually transmitted infection in the U.S. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to human papillomavirus infection. CDC also states that about 14 million people are newly infected by human papillomavirus every year in the U.S. According to the Cancer Council Australia, almost all schools in Australia have chosen to participate in the National Human Papillomavirus Vaccination Program. More than 9 million doses of vaccine have been given to girls and young women in Australia. This initiation resulted in approximately 90% decrease in genital warts among heterosexual women and men under the age of 21 years and approximately 50% decrease in disease of high-grade cervical abnormalities in girls under 18 years of age.

global human papillomavirus vaccine market

High unmet needs are expected to create huge opportunities for existing players and new entrants in the global human papillomavirus vaccine market. These vaccines are used against various types of human papillomavirus, which provides ample opportunities for players operating in the global human papillomavirus vaccines market. Recent developments in research and development of human papillomavirus vaccines fuel the growth of the market during the forecast period. In December 2015, Merck & Co., Inc. announced that the U.S. FDA has approved an extended age indication for Gardasil 9, a nonavalent human papillomavirus vaccine to include use in males 16 to 26 years of age for the prevention of anal and penile cancers and genital warts caused by certain human papillomavirus types.

Human Papillomavirus Vaccine Market: Segmentation

The global human papillomavirus vaccine market has been categorized based on quadrivalent, and nonavalent and region. Quadrivalent, and nonavalent segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by bivalent segment. The launch of new and increasing incidences of cervical cancer are likely to propel the segment. In terms of indication type, cervical cancer dominated the segment in 2016 and it is anticipated to continue its dominance during the forecast period. Anal cancer was the second most leading segment in 2016 and it is likely to continue this trend from 2017 to 2025. Based on distribution channel, government entities held the largest share of the market. However, the segment is anticipated to lose market share during the forecast period owing to public and private alliances such as GAVI that are focused on vaccinating people in developing countries

Geographically, North America accounted for the largest share of global human papillomavirus vaccine market in 2016. Recent approvals received by key players of the market in the region are attributed for increase market share of the region. The market share of Asia Pacific is projected to increase during the forecast period. In July 2017, GlaxoSmithKline plc. Received approval for Cervarix from China FDA. This is anticipated to drive the human papillomavirus vaccine market in the region. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals is likely to boost the market in Latin America and Middle East & Africa.

Key players operating in the global human papillomavirus vaccine market include Merck & Co., Inc., GlaxoSmithKline plc. Sanofi, Johnson & Johnson, AstraZeneca, and Serum Institute of India Pvt. Ltd. These players adopted inorganic and organic growth strategies to increase their vaccine offerings, strengthen their reach across the globe, garner market share, and increase customer base.

The global human papillomavirus vaccine market has been segmented as below:

Valence

  • Bivalent
  • Quadrivalent and Nonavalent

Indication

  • Cervical Cancer
  • Anal Cancer
  • Vaginal Cancer
  • Penile Cancer
  • Vulvar Cancer
  • Oropharyngeal Cancer
  • Genital Warts
  • Others

Distribution Channel

  • Physicians
  • Wholesalers
  • Physician Distributors
  • Government Entities
  • Public and Private Alliances

 Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
Human Papillomavirus Vaccine Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1.  Preface
     1.1. Market Segmentation
     1.2. Key Research Objectives
     1.3. Research Highlights

2.  Assumptions and Acronyms Used

3. Research Approach & Methodology
     3.1. Research Methodology Overview
     3.2. Project Initiation
     3.3. Secondary Research Methodology
     3.4. Primary Research Methodology
     3.5. Analysis Research Methodology
     3.6. Final Report & Conclusions Research Methodology

4. Executive Summary: Global Human Papillomavirus Vaccine Market

5.  Market Overview
     5.1. Overview
     5.2. Key Industry Events and Developments
     5.3. Global Human Papillomavirus Vaccine Market Forecast and Analysis
     5.4. Global Human Papillomavirus Vaccine Market Outlook

6. Market Dynamics
     6.1. Drivers and Restraints Snapshot Analysis
     6.2. Drivers
     6.3. Restraints
     6.4. Opportunity
     6.5. Key Trends
     6.6. Institutional Sales Overview, by Volume (No. of Unit Dose)
     6.7. Pricing Analysis
     6.8. Pipeline Analysis: Human Papillomavirus Vaccine

7. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Valence
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast by Valence, 2015–2025
            7.3.1. Bivalent
            7.3.2. Quadrivalent, and Nonavalent
     7.4. Global Human Papillomavirus Vaccines Market Analysis, by Valence
     7.5. Global Human Papillomavirus Vaccines Market Forecast, by Valence
     7.6. Global Human Papillomavirus Vaccines Market Analysis, by Valence

8. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Indication
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Market Value Forecast by Indication, 2015–2025
            8.3.1. Cervical Cancer
            8.3.2. Anal Cancer
            8.3.3. Vaginal Cancer
            8.3.4. Penile Cancer
            8.3.5. Vulvar Cancer
            8.3.6. Oropharyngeal Cancer
            8.3.7. Genital Warts
            8.3.8. Others
     8.4. Global Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
     8.5. Global Human Papillomavirus Vaccines Market Forecast, by Indication
     8.6. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Indication

9. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Distribution Channel
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Market Value Forecast by Distribution Channel, 2015–2025
            9.3.1. Physicians
            9.3.2. Wholesalers
            9.3.3. Physician Distributors
            9.3.4. Government Entities
            9.3.5. Public and Private Alliances
     9.4. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel
     9.5. Global Human Papillomavirus Vaccines Market Forecast, by Distribution Channel
     9.6. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel

10. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Region
     10.1. Global Human papillomavirus vaccine Market Snapshot, by Country
     10.2. Global Human Papillomavirus Vaccines Market Analysis, by Region
            10.2.1. North America
            10.2.2. Europe
            10.2.3. Asia Pacific
            10.2.4. Latin America
            10.2.5. Middle East & Africa
     10.3. Global Human Papillomavirus Vaccines Market Forecast, by Region
     10.4. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Region

11. North America Human Papillomavirus Vaccine Market Analysis
     11.1. Policies and Regulations
     11.2. Key Findings
     11.3. North America Human Papillomavirus Vaccines Market Overview
     11.4. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
            11.4.1. U.S.
            11.4.2. Canada
     11.5. Market Attractiveness Analysis
     11.6. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
            11.6.1. Bivalent
            11.6.2. Quadrivalent, and Nonavalent
     11.7. Market Attractiveness Analysis
     11.8. North America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
            11.8.1. Cervical Cancer
            11.8.2. Anal Cancer
            11.8.3. Vaginal Cancer
            11.8.4. Penile Cancer
            11.8.5. Vulvar Cancer
            11.8.6. Oropharyngeal Cancer
            11.8.7. Genital Warts
            11.8.8. Others
     11.9. Market Attractiveness Analysis
     11.10. Market Value Share Analysis by Distribution Channel, 2015–2025
            11.10.1. Physicians
            11.10.2. Wholesalers
            11.10.3. Physician Distributors
            11.10.4. Government Entities
            11.10.5. Public and Private Alliances

12. Europe Human Papillomavirus Vaccine Market Analysis
     12.1. Policies and Regulations
     12.2. Key Findings
     12.3. Europe Human Papillomavirus Vaccines Market Overview
     12.4. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
            12.4.1. Germany
            12.4.2. France
            12.4.3. Italy
            12.4.4. Spain
            12.4.5. U.K.
            12.4.6. Rest of Europe
     12.5. Market Attractiveness Analysis
     12.6. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
            12.6.1. Bivalent
            12.6.2. Quadrivalent, and Nonavalent
     12.7. Market Attractiveness Analysis
     12.8. Europe Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
            12.8.1. Cervical Cancer
            12.8.2. Anal Cancer
            12.8.3. Vaginal Cancer
            12.8.4. Penile Cancer
            12.8.5. Vulvar Cancer
            12.8.6. Oropharyngeal Cancer
            12.8.7. Genital Warts
            12.8.8. Others
     12.9. Market Attractiveness Analysis
     12.10. Market Value Share Analysis by Distribution Channel, 2015–2025
            12.10.1. Physicians
            12.10.2. Wholesalers
            12.10.3. Physician Distributors
            12.10.4. Government Entities
            12.10.5. Public and Private Alliances

13. Asia Pacific Human Papillomavirus Vaccine Market Analysis
     13.1. Policies and Regulations
     13.2. Key Findings
     13.3. Asia Pacific Human Papillomavirus Vaccines Market Overview
     13.4. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
            13.4.1. China
            13.4.2. Japan
            13.4.3. India
            13.4.4. Australia & New Zealand
            13.4.5. Rest of Asia Pacific
     13.5. Market Attractiveness Analysis
     13.6. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
            13.6.1. Bivalent
            13.6.2. Quadrivalent, and Nonavalent
     13.7. Market Attractiveness Analysis
     13.8. Asia Pacific Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
            13.8.1. Cervical Cancer
            13.8.2. Anal Cancer
            13.8.3. Vaginal Cancer
            13.8.4. Penile Cancer
            13.8.5. Vulvar Cancer
            13.8.6. Oropharyngeal Cancer
            13.8.7. Genital Warts
            13.8.8. Others
     13.9. Market Attractiveness Analysis
     13.10. Market Value Share Analysis by Distribution Channel, 2015–2025
            13.10.1. Physicians
            13.10.2. Wholesalers
            13.10.3. Physician Distributors
            13.10.4. Government Entities
            13.10.5. Public and Private Alliances

14. Latin America Human Papillomavirus Vaccine Market Analysis
     14.1. Policies and Regulations
     14.2. Key Findings
     14.3. Latin America Human Papillomavirus Vaccines Market Overview
     14.4. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
            14.4.1. Brazil
            14.4.2. Mexico
            14.4.3. Rest of Latin America
     14.5. Market Attractiveness Analysis
     14.6. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
            14.6.1. Bivalent
            14.6.2. Quadrivalent, and Nonavalent
     14.7. Market Attractiveness Analysis
     14.8. Latin America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
            14.8.1. Cervical Cancer
            14.8.2. Anal Cancer
            14.8.3. Vaginal Cancer
            14.8.4. Penile Cancer
            14.8.5. Vulvar Cancer
            14.8.6. Oropharyngeal Cancer
            14.8.7. Genital Warts
            14.8.8. Others
     14.9. Market Attractiveness Analysis
     14.10. Market Value Share Analysis by Distribution Channel, 2015–2025
            14.10.1. Physicians
            14.10.2. Wholesalers
            14.10.3. Physician Distributors
            14.10.4. Government Entities
            14.10.5. Public and Private Alliances

15. Middle East & Africa Human Papillomavirus Vaccine Market Analysis
     15.1. Policies and Regulations
     15.2. Key Findings
     15.3. Middle East & Africa Human Papillomavirus Vaccines Market Overview
     15.4. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
            15.4.1. GCC Countries
            15.4.2. South Africa
            15.4.3. Rest of Middle East & Africa
     15.5. Market Attractiveness Analysis
     15.6. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
            15.6.1. Bivalent
            15.6.2. Quadrivalent, and Nonavalent
     15.7. Market Attractiveness Analysis
     15.8. Middle East & Africa Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
            15.8.1. Cervical Cancer
            15.8.2. Anal Cancer
            15.8.3. Vaginal Cancer
            15.8.4. Penile Cancer
            15.8.5. Vulvar Cancer
            15.8.6. Oropharyngeal Cancer
            15.8.7. Genital Warts
            15.8.8. Others
     15.9. Market Attractiveness Analysis
     15.10. Market Value Share Analysis by Distribution Channel, 2015–2025
            15.10.1. Physicians
            15.10.2. Wholesalers
            15.10.3. Physician Distributors
            15.10.4. Government Entities
            15.10.5. Public and Private Alliances

16. Competition Landscape
     16.1. Human Papillomavirus (HPV) Vaccine Sales Analysis
     16.2. Competition Matrix
     16.3. Human Papillomavirus (HPV) Vaccine Market Share Analysis, by Company
     16.4. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            16.4.1. Merck & Co., Inc.
                     16.4.1.1. Company Description
                     16.4.1.2. Financial Overview
                     16.4.1.3. Strategic Overview
                     16.4.1.4. Recent Developments
                     16.4.1.5. SWOT ANALYSIS
            16.4.2. GlaxoSmithKline plc.
                     16.4.2.1. Company Description
                     16.4.2.2. Financial Overview
                     16.4.2.3. Strategic Overview
                     16.4.2.4. Recent Developments
                     16.4.2.5. SWOT ANALYSIS
            16.4.3. Sanofi
                     16.4.3.1. Company Description
                     16.4.3.2. Financial Overview
                     16.4.3.3. Strategic Overview
                     16.4.3.4. SWOT ANALYSIS
            16.4.4. Johnson & Johnson
                     16.4.4.1. Company Description
                     16.4.4.2. Financial Overview
                     16.4.4.3. Recent Developments
                     16.4.4.4. SWOT ANALYSIS
            16.4.5. AstraZeneca
                     16.4.5.1. Company Description
                     16.4.5.2. Financial Overview
                     16.4.5.3. Recent Developments
                     16.4.5.4. SWOT ANALYSIS
            16.4.6. Serum Institute of India Pvt. Ltd.
                     16.4.6.1. Company Description
                     16.4.6.2. Recent Developments
                     16.4.6.3. SWOT ANALYSIS
            16.4.7. Xiamen Innovax Biotech CO., LTD. (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)
                     16.4.7.1. Company Description
                     16.4.7.2. SWOT ANALYSIS
            16.4.8. General Incorporated Foundation, The Chemo- Sero-Therapeutic Research Institute (Kaketsuken)
                     16.4.8.1. Company Description
                     16.4.8.2. Recent Developments
                     16.4.8.3. SWOT ANALYSIS
            16.4.9. Bharat Biotech
                     16.4.9.1. Company Description
                     16.4.9.2. SWOT ANALYSIS

List of Tables

Table 01: Opportunity Map, by Valence 2016
Table 02: Opportunity Map, by Indication 2016
Table 03: Opportunity Map, by Distribution Channel 2016
Table 04: Pipeline Analysis
Table 05: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valence, 2015–2025
Table 06: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 07: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 08: Global Human Papillomavirus Vaccines Market (US$ Mn) Forecast, by Region, 2015–2025
Table 09: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 10: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 11: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 12: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 15: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 16: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 18: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 19: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 20: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 22: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 23: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 24: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 26: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 27: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 28: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 29: Human Papillomavirus (HPV) Vaccine Sales Analysis, 2014 – 2016

List of Figures

Figure 01: Global Human Papillomavirus Vaccines Market, by Valence, Market Size (US$ Mn), 2016 (A)
Figure 02: Global Human Papillomavirus Vaccines Market Revenue (%), by Indication, 2016 (A)
Figure 03: By Valence Revenue (%), 2016
Figure 04: By Indication Opportunity Map, 2016
Figure 05: Vaccine Type Opportunity Map, 2016
Figure 06: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, 2015–2025
Figure 07: Market Value Share, by Valence (2016)
Figure 08: Market Value Share, by Indication (2016)
Figure 09: Market Value Share, by Distribution Channel (2016)
Figure 10: Market Value Share, by Region (2016)
Figure 11: Global Human Papillomavirus Vaccines Market Value Share, by Valence, 2016 and 2025
Figure 12: Global Human Papillomavirus Vaccines Market Attractiveness, by Valence, 2017–2025
Figure 13: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bivalent, 2015–2025
Figure 14: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Quadrivalent, and Nonavalent, 2015–2025
Figure 15: Global Human Papillomavirus Vaccines Vaccines Market Value Share Analysis, by Indication, 2016 and 2025
Figure 16: Global Cervical Cancer Market Revenue, US$ Mn, 2017–2025
Figure 17: Global Anal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 18: Global Vaginal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 19: Global Penile Cancer Market Revenue, US$ Mn, 2017–2025
Figure 20: Global Vulvar Cancers Market Revenue, US$ Mn, 2017–2025
Figure 21: Global Oropharyngeal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 22: Global Genital Warts Market Revenue, US$ Mn, 2017–2025
Figure 23: Global Others Market Revenue, US$ Mn, 2017–2025
Figure 24: Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Indication
Figure 25: Global Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 26: Global Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 27: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Wholesalers Vaccines, 2015–2025
Figure 28: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Physicians Vaccines, 2015–2025
Figure 29: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Government Entities Vaccine, 2015–2025
Figure 30: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Physician Distributors Vaccine, 2015–2025
Figure 31: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Other Vaccines, 2015–2025
Figure 32: Global Human Papillomavirus Vaccines Market Analysis by Region, 2016 and 2025
Figure 33: Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Region
Figure 34: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 35: North America Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 36: North America Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 37: North America Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 38: North America Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 39 highlights market value share of the HPV vaccines market in Europe, by indication, for 2016 and 2025.
Figure 39: North America Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 40: North America Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 41: North America Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 42: North America Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 43: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 44: Europe Human Papillomavirus Vaccines Market Value Share, by Country, 2016 and 2025
Figure 45: Europe Human Papillomavirus Vaccines Market Attractiveness, by Country, 2017–2025
Figure 46: Europe Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 47: Europe Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 48: Europe Human Papillomavirus Vaccines Market Value Share, by Indication, 2015 and 2025
Figure 49: Europe Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 50: Europe Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 51: Europe Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 52: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 53: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 54: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 55: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 56: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 57: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 58: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 59: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 60: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 61: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 62: Latin America Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 63: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 64: Latin America Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 65: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 66: Latin America Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 67: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 68: Latin America Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 69: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 70: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 71: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 72: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 73: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 74: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 75: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 76: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 77: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 78: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 79: Human Papillomavirus (HPV) Vaccine Market Share, by Company, 2016

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

447

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved